Get patients started with a 4-week Titration Kit right arrow

Now available through sample or prescription

close Close

The 1st VMAT2 inhibitor approved for both TD and HD chorea1

Now Available once-daily dosing.
HD Chorea Campaign Banner
HD Chorea Campaign Banner

For adults with TD or HD chorea

Make a

move that



*Symptom control defined as change in AIMS total score observed as early as Week 2 in placebo-controlled studies.2,3

Patients in the pivotal and 3-year studies received the AUSTEDO BID formulation.1,5

Orange Video Icon

Mechanism of Action:

VMAT2 inhibition can help regulate dopamine function.6

AIMS, Abnormal Involuntary Movement Scale; HD, Huntington’s disease; TD, tardive dyskinesia; VMAT2, vesicular monoamine transporter 2.

REFERENCES: 1. AUSTEDO® XR (deutetrabenazine) extended-release tablets and AUSTEDO® current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 2. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. 3. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88(21):2003-2010. 4. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 5. Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. Front Neurol. 2022;13:773999. doi:10.3389/fneur.2022.773999 6. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215-1238.